PHG KONINKLIJKE PHILIPS NV IFRS Annual reports only
X-Ray Apparatus & Tubes & Related Irradiation Apparatus · NYSE · SEC CIK 313216 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 17.83B | 18.02B | 18.17B | 17.83B | 17.16B |
| Cost of revenue | 9.78B | 10.25B | 10.72B | 10.63B | 9.99B |
| Gross profit | 8.06B | 7.77B | 7.45B | 7.19B | 7.17B |
| R&D expense | 1.70B | 1.75B | 1.89B | 2.09B | 1.81B |
| SG&A expense | 628.00M | 582.00M | 608.00M | 671.00M | 599.00M |
| Operating income | 1.42B | 529.00M | -115.00M | -1.53B | 553.00M |
| Interest expense | 288.00M | 288.00M | 277.00M | 235.00M | 159.00M |
| Pretax income | 1.18B | 123.00M | -526.00M | -1.73B | 509.00M |
| Income tax | 282.00M | 963.00M | -73.00M | -113.00M | -103.00M |
| Net income | 895.00M | -702.00M | -466.00M | -1.61B | 3.32B |
| EBITDA | 2.55B | 1.92B | 1.15B | 73.00M | 1.88B |
| EPS (basic) | 0.94 | -0.75 | -0.49 | -1.69 | 3.52 |
| EPS (diluted) | 0.93 | -0.75 | -0.49 | -1.69 | 3.50 |
| Weighted avg. shares (diluted) | 962.50M | 933.37M | 948.30M | 951.81M | — |
| Balance sheet | |||||
| Cash & equivalents | 2.79B | 2.40B | 1.87B | 1.17B | 2.30B |
| Receivables | 3.53B | 3.67B | 3.73B | 4.12B | 3.79B |
| Inventory | 2.87B | 3.20B | 3.49B | 4.05B | 3.45B |
| Current assets | 9.93B | 10.02B | 9.94B | 10.26B | 10.35B |
| PP&E, netmay include right-of-use assets (IFRS) | 2.22B | 2.45B | 2.48B | 2.64B | 2.70B |
| Goodwill | 9.27B | 10.38B | 9.88B | 10.24B | 10.64B |
| Intangibles | 2.57B | 2.98B | 3.19B | 3.53B | 3.65B |
| Total assets | 26.94B | 28.98B | 29.41B | 30.69B | 30.96B |
| Current liabilities | 7.51B | 8.15B | 8.29B | 7.93B | 7.45B |
| Short-term debt | 1.15B | 526.00M | 654.00M | 931.00M | 506.00M |
| Long-term debt | 6.93B | 7.11B | 7.04B | 7.27B | 6.47B |
| Total debt | 8.09B | 7.64B | 7.69B | 8.20B | 6.98B |
| Total liabilities | 15.95B | 16.93B | 17.34B | 17.41B | 16.49B |
| Shareholders' equity | 10.96B | 12.01B | 12.03B | 13.25B | 14.44B |
| Net debt | 5.29B | 5.24B | 5.82B | 7.03B | 4.68B |
| Cash flow statement | |||||
| Operating cash flow | — | — | — | — | — |
| Capital expenditure | 269.00M | 317.00M | 345.00M | 444.00M | 397.00M |
| Depreciation & amortization | 1.12B | 1.39B | 1.26B | 1.60B | 1.32B |
| Stock-based compensation | 141.00M | 96.00M | 88.00M | 95.00M | 108.00M |
| Dividends paid | 330.00M | 32.00M | 70.00M | 418.00M | 484.00M |
| Share buybacks | 0 | 411.00M | 662.00M | 187.00M | 1.64B |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.